In this KEVETRIN study that just started really - Even though I am not a bio-scientist , does the SIZE of the study (meaning the number of participants) have a lot of bearing on the DATA ? Seems to me that the large the number the more reliable the DATA collected. I know they are increasing that number along the way but what number do they need to get full creability by other institutions? After all PHIZER wants to start thier own study with KEVETRIN plus one of thier own inhouse drugs but are waiting on DANA-FABER. So they must have thier own requirements before they start.
